These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 9097768)
21. Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% apraclonidine. Pollack IP; Brown RH; Crandall AS; Robin AL; Stewart RH; White GL Arch Ophthalmol; 1988 Jun; 106(6):754-7. PubMed ID: 3369999 [TBL] [Abstract][Full Text] [Related]
22. Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy. Seong GJ; Lee YG; Lee JH; Lim SJ; Lee SC; Hong YJ; Kwon OW; Kim HB Ophthalmic Surg Lasers; 2000; 31(4):308-14. PubMed ID: 10928668 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of apraclonidine in preventing the rise in intraocular pressure after neodymium:YAG posterior capsulotomy. Pollack IP; Brown RH; Crandall AS; Robin AL; Stewart RH; White GL Trans Am Ophthalmol Soc; 1988; 86():461-72. PubMed ID: 2979050 [TBL] [Abstract][Full Text] [Related]
24. Topical 2.0% dorzolamide vs oral acetazolamide for prevention of intraocular pressure rise after neodymium:YAG laser posterior capsulotomy. Ladas ID; Baltatzis S; Panagiotidis D; Zafirakis P; Kokolakis SN; Theodossiadis GP Arch Ophthalmol; 1997 Oct; 115(10):1241-4. PubMed ID: 9338667 [TBL] [Abstract][Full Text] [Related]
25. ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery. Brown RH; Stewart RH; Lynch MG; Crandall AS; Mandell AI; Wilensky JT; Schwartz AL; Gaasterland DE; DeFaller JM; Higginbotham EJ Ophthalmology; 1988 Mar; 95(3):378-84. PubMed ID: 3050686 [TBL] [Abstract][Full Text] [Related]
26. Failure of apraclonidine to prevent delayed IOP elevation after Nd:YAG laser posterior capsulotomy. Nesher R; Kolker AE Trans Am Ophthalmol Soc; 1990; 88():229-32; discussion 233-6. PubMed ID: 1982748 [TBL] [Abstract][Full Text] [Related]
27. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group. Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690 [TBL] [Abstract][Full Text] [Related]
28. Effect of Apraclonidine and Diclofenac on Early Changes in Intraocular Pressure After Selective Laser Trabeculoplasty. Thrane VR; Thrane AS; Bergo C; Halvorsen H; Krohn J J Glaucoma; 2020 Apr; 29(4):280-286. PubMed ID: 32053556 [TBL] [Abstract][Full Text] [Related]
29. Early intraocular pressure response to laser trabeculoplasty 180 degrees without apraclonidine versus 360 degrees with apraclonidine. Allf BE; Shields MB Ophthalmic Surg; 1991 Sep; 22(9):539-42. PubMed ID: 1682861 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness of apraclonidine 1% in preventing intraocular pressure rise following macular hole surgery. Sciscio A; Casswell AG Br J Ophthalmol; 2001 Feb; 85(2):164-8. PubMed ID: 11159479 [TBL] [Abstract][Full Text] [Related]
32. Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma. Nishimoto JH; Chang FW; Tang IH; Kolin T J Am Optom Assoc; 1999 Apr; 70(4):233-9. PubMed ID: 10457699 [TBL] [Abstract][Full Text] [Related]
33. Prophylactic use of apraclonidine for intraocular pressure increase after Nd:YAG capsulotomies. Silverstone DE; Brint SF; Olander KW; Taylor RB; McCarty GR; deFaller JM; Burk LL Am J Ophthalmol; 1992 Apr; 113(4):401-5. PubMed ID: 1348396 [TBL] [Abstract][Full Text] [Related]
34. Prophylactic use of apraclonidine for intraocular pressure increase after Nd:YAG Capsulotomies. Romanowski A Am J Ophthalmol; 1992 Sep; 114(3):377-9. PubMed ID: 1355949 [No Abstract] [Full Text] [Related]
35. Influence of apraclonidine and pilocarpine alone and in combination on post laser trabeculoplasty pressure rise. Dapling RB; Cunliffe IA; Longstaff S Br J Ophthalmol; 1994 Jan; 78(1):30-2. PubMed ID: 7906539 [TBL] [Abstract][Full Text] [Related]
36. Effects of 0.5% and 0.25% apraclonidine on postoperative intraocular hypertension after cataract extraction. Simşek S; Demirok A; Yaşar T; Cinal A; Bayram A; Yilmaz OF Eur J Ophthalmol; 1998; 8(2):67-70. PubMed ID: 9673473 [TBL] [Abstract][Full Text] [Related]
37. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy. Yeom HY; Lee JH; Hong YJ; Seong GJ J Ocul Pharmacol Ther; 2006 Jun; 22(3):176-81. PubMed ID: 16808678 [TBL] [Abstract][Full Text] [Related]
38. Effects of apraclonidine on aqueous humor dynamics in human eyes. Toris CB; Tafoya ME; Camras CB; Yablonski ME Ophthalmology; 1995 Mar; 102(3):456-61. PubMed ID: 7891985 [TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of acetazolamide and apraclonidine in the control of intraocular pressure following phacoemulsification. Scuderi G; Regine F; Perdicchi A; Mannino G; Recupero SM Ophthalmologica; 2006; 220(6):356-60. PubMed ID: 17095879 [TBL] [Abstract][Full Text] [Related]
40. The effect of 1% apraclonidine on intraocular pressure after cataract surgery. Sterk CC; Renzenbrink-Bubberman AC; van Best JA Ophthalmic Surg Lasers; 1998 Jun; 29(6):472-5. PubMed ID: 9640568 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]